Latest stories on GOSS
Gossamer Bio Regains Full Rights to Seralutinib with Clarity on Regulatory Path and Strengthened Balance Sheet
MarketChameleon67 · bullishproduct/pr
Leerink upgrades Gossamer Bio stock rating on FDA feedback
Investing.com Analyst Ratings61 · neutralanalyst
Gossamer Bio, Inc. (GOSS) files 8-K
SEC 8-K50 · neutralgeneral
Gossamer Bio Locks in Global Rights and Regulatory Path for Seralutinib—Strengthened Balance Sheet Provides Flexibility
July 27, 2026
MarketChameleon73 · bullishproduct/pr
Gossamer Bio shares jump after FDA update and seralutinib rights return
InvestorsHub68 · bullishproduct/pr
Gossamer Bio shares jump after FDA update and seralutinib rights return
Yahoo Top73 · bullishgeneral
Why is Gossamer Bio stock surging today?
Investing.com Markets50 · neutralgeneral
Gossamer Bio Sets Conversion Terms for Convertible Notes
TipRanks48 · neutralgeneral
Gossamer Bio, Inc. (GOSS) files 8-K
SEC 8-K50 · neutralgeneral
Gossamer Bio Announces Final Convertible Notes Exchange Results
TipRanks50 · neutralgeneral
Gossamer Bio, Inc. (GOSS) files 8-K
SEC 8-K50 · neutralgeneral
Gossamer Bio shareholders reaffirm board and governance structure
TipRanks50 · neutralgeneral
Gossamer Bio Restructures Capital Through Convertible Notes Exchange
TipRanks28 · bearishgeneral
Gossamer Bio Extends Early Deadline in Note Exchange
TipRanks50 · neutralgeneral
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Business Insider34 · bearishgeneral
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Morningstar34 · bearishgeneral
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS
Morningstar34 · bearishgeneral